Understanding the disease is the first step toward effective treatment. BPH is the most common urological condition in men over 50, yet it remains highly undertreated.
Benign Prostatic Hyperplasia (BPH) is a non-cancerous, progressive enlargement of the prostate gland that compresses the urethra and gradually obstructs urinary flow. Although it is not life-threatening, its impact on quality of life is profound.
20–30 g in a young adult, located below the bladder, surrounding the urethra. It plays a role in seminal fluid production.
From age 40, male hormones trigger slow, continuous prostate growth. By age 60, 50% of men are affected; by age 85, 90%.
As the gland enlarges, it compresses the urethra, reducing urinary flow progressively. This mechanical obstruction generates a range of symptoms.
BPH produces two complementary categories of signs.
The therapeutic strategy is tailored to symptom severity, patient profile, and individual preferences.
For mild symptoms (I-PSS ≤ 7). Lifestyle modification: limit evening fluids, reduce caffeine/alcohol, pelvic floor exercises, regular monitoring.
Alpha-blockers (relaxes smooth muscle), 5-alpha-reductase inhibitors (reduces prostate volume). Effective short-term but requires ongoing use and has side effects.
Gold standard for moderate symptoms. Water vapor destroys obstructive tissue. 10 minutes, outpatient, no major surgery, preserves sexual function, durable.
Reserved for severe cases or very large prostates (>80 cc). Requires general anesthesia and hospitalization. Risk of retrograde ejaculation and erectile dysfunction.
The International Prostate Symptom Score (I-PSS) is the international reference scale for evaluating urological symptoms and guiding treatment decisions.
This questionnaire is for informational purposes only and does not replace a medical consultation.